NBIX Analyst Upgrade
TD Cowen Boosts Neurocrine Biosciences Price Target, Analysts Maintain Strong Buy Ratings
Anonymous
TD Cowen has raised its price target for Neurocrine Biosciences (NASDAQ:NBIX) from $200.00 to $220.00, signaling strong confidence in the drugmaker's outlook, according to MarketBeat. The new target implies a potential upside of roughly 32% from the stock's recent closing price.
The upgrade adds to a growing wave of Wall Street optimism around NBIX. The stock currently holds a consensus rating of "Moderate Buy" and an average analyst price target of $199.14, per MarketBeat.
TD Cowen Lifts Target to $220 in Bold Call
TD Cowen's move from a $200 to a $220 price target is one of the most bullish calls on NBIX in recent months. A 32% upside from the stock's previous close is a significant gap. That kind of gap suggests analysts see real catalysts ahead, not just routine optimism, according to MarketBeat.
TD Cowen has been active across multiple sectors lately. The firm also raised its 2027 price target for Amazon to $350 from $340, citing stronger cloud growth and better operating performance, per Yahoo Finance.
Wall Street Zen and Royal Bank Also Turn Bullish
Wall Street Zen upgraded Neurocrine Biosciences from a "buy" to a "strong buy" on April 25th, according to MarketBeat. That is a rare step up — most firms stay at "buy" and rarely push to the stronger label.
Royal Bank of Canada also joined the bull camp. The bank raised its price target on NBIX to $183.00 and gave the stock an "outperform" rating in a July 7th report. Multiple firms moving in the same direction at once is a signal worth noting, per MarketBeat.
Consensus Rating Sits at Moderate Buy With Room to Run
Across all analyst ratings, NBIX holds a consensus of "Moderate Buy" with an average target price of $199.14, according to MarketBeat. TD Cowen's new $220 target sits well above that average. If more firms follow TD Cowen's lead, the consensus target could move higher.
The gap between the $199.14 average target and TD Cowen's $220 call is about $21. That spread shows not all analysts are equally confident yet. But the direction of recent upgrades points clearly upward.
What NBIX Does and Why Analysts Are Watching
Neurocrine Biosciences is a San Diego-based drugmaker focused on brain and nervous system conditions. Its flagship drug, Ingrezza, treats tardive dyskinesia — a movement disorder caused by certain medications. Ingrezza has been a strong revenue driver and is a key reason analysts are bullish on the stock.
With multiple analysts raising targets and TD Cowen leading with a $220 call, investors are clearly watching NBIX closely. A 32% implied upside from the previous close is not something Wall Street posts lightly, per MarketBeat.
Sentiment
NeutralNEGATIVENEUTRALPOSITIVE
Publishers
4
Articles
4
Reach
7
A
AnonymousAuthor